Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases

References

• Katsanos KH, Papamichael K, Feuerstein JD, et al. Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin Immunol. 2018 Mar 12;S1521-6616(17)30901–4. Epub ahead of print. DOI:10.1016/j.clim.2018.03.004
   PubMed Web of Science ®Google Scholar
• Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187.
   PubMed Web of Science ®Google Scholar
• Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13(12):707–718.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Vande Casteele N, Ferrante M, et al. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window. Inflamm Bowel Dis. 2017;23(9):1510–1515.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Lambert J, Nast A, Nestle FO, et al. Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: what can be learnt from other diseases? J Dermatolog Treat. 2015;26(6):520–527.
   PubMed Web of Science ®Google Scholar
• Ungar B, Engel T, Yablecovitch D, et al. Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC study. Am J Gastroenterol. 2018;113(6):890–898.
   PubMed Web of Science ®Google Scholar
• Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther. 2018;47(2):212–218.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Moors G, Bian S, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018;48(7):731–739.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Van Stappen T, Ballet V, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response. Aliment Pharmacol Ther. 2018;47(3):346–355.
   PubMed Web of Science ®Google Scholar
• Chen D-Y, Chen Y-M, Tsai W-C, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74:e16.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–926.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert C, Nurmohamed M, et al. development of antidrug antibodies against adalimumab and association. JAMA Intern Med. 2011;305(14):1460–1468.
   Google Scholar
• Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73(12):2178–2182.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Wei J-C-C, Nurmohamed MT, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2015;74(2):396–401.
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50(8):1445–1452.
   PubMed Web of Science ®Google Scholar
• Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955–1960.
   PubMed Web of Science ®Google Scholar
• de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66(9):1252–1254.
   PubMed Web of Science ®Google Scholar
• Radstake TRDJ, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739–1745.
   PubMed Web of Science ®Google Scholar
• Bito T, Nishikawa R, Hatakeyama M, et al. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol. 2014;170(4):922–929.
   PubMed Web of Science ®Google Scholar
• Menting SP, van Den Reek JM, Baerveldt EM, et al. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. Br J Dermatol. 2015;173(3):855–857.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Arkir Z, Richards G, et al. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol. 2013;169(2):306–313.
   PubMed Web of Science ®Google Scholar
• Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–530.
   PubMed Web of Science ®Google Scholar
• Restellini S, Chao CY, Lakatos PL, et al. therapeutic drug monitoring guides the management of crohn’s patients with secondary loss of response to adalimumab. Inflamm Bowel Dis. 2018;24(7):1531–1538.
   PubMed Web of Science ®Google Scholar
• Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109(8):1250–1256.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284–288.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–927.
   PubMed Web of Science ®Google Scholar
• Guidi L, Pugliese D, Panici Tonucci T, et al. Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. J Crohns Colitis. 2018 May 31. [ Epub ahead of print]. DOI:10.1093/ecco-jcc/jjy076
   PubMedGoogle Scholar
• Kelly OB, Donnell SO, Stempak JM, et al. Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(7):1202–1209.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Jeyarajah J, Jairath V, et al. Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2018 Oct 26;S1542-3565(18)31200-X. Epub ahead of print. DOI:10.1016/j.cgh.2018.10.036
   PubMed Web of Science ®Google Scholar
• Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(4):543–549.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Baert F, Laharie D, et al. Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn’s disease. Clin Gastroenterol Hepatol. 2019 May 22;S1542-3565(19)30551–8. Epub ahead of print. DOI:10.1016/j.cgh.2019.05.029
   PubMedGoogle Scholar
• Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–1307.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Papamichael K, Jeyarajah J, et al. Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial. J Crohn’s Colitis. 2019;13(Supplement_1):S053–S054.
   Google Scholar
• Kennedy NA, Heap GA, Harry D, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019 Feb 26;S2468-1253(19)30012–3. Epub ahead of print. DOI:10.1016/S2468-1253(19)30012-3
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rakowsky S, Rivera C, et al. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic and histologic remission in Crohn’s disease. Inflamm Bowel Dis. 2018;24(10):2266–2271.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rakowsky S, Rivera C, et al. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):478–484.
   PubMed Web of Science ®Google Scholar
• Juncadella A, Papamichael K, Vaughn B, et al. Maintenance adalimumab concentrations are associated with biochemical, endoscopic and histologic remission in inflammatory bowel disease. Dig Dis Sci. 2001 Jul 13. Epub ahead of print. DOI:10.1007/s10620-018-5202-5
   Google Scholar
• Vande Casteele N, Baert F, Bian S, et al. Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn’s disease: a prospective multicentre study. J Crohn’s Colitis. 2019 Mar 1;jjz050. Epub ahead of print. DOI:10.1093/ecco-jcc/jjz050
   Google Scholar
• Nakase H, Motoya S, Matsumoto T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017;46(9):873–882.
   PubMed Web of Science ®Google Scholar
• Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014;40(11–12):1324–1332.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Baert F, Tops S, et al. Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis. J Crohns Colitis. 2017;11(1):53–59.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Feagan BG, Vermeire S, et al. Exposure–response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn’s disease. Aliment Pharmacol Ther. 2018;47(2):229–237.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2017;11(1):35–46.
   PubMed Web of Science ®Google Scholar
• Detrez I, Dreesen E, Van Stappen T, et al. Variability in golimumab exposure: a ‘real-life’ observational study in active ulcerative colitis. J Crohns Colitis. 2016;10(5):575–581.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Rosario M, Lasch K, et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther. 2019;49(4):408–418.
   PubMed Web of Science ®Google Scholar
• Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(12):1937–1946.
   PubMed Web of Science ®Google Scholar
• Pouillon L, Rousseau H, Busby-Venner H, et al. Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis. J Crohns Colitis. 2019. Epub ahead of print. DOI:10.1093/ecco-jcc/jjz029
   PubMedGoogle Scholar
• Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease. Gastroenterology. 2018;154(6):1660–1671.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in Crohn’s disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019 Jan 30. [ Epub ahead of print]. DOI:10.1093/ecco-jcc/jjz008
   Google Scholar
• Battat R, Kopylov U, Bessissow T, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15(9):1427–1434.
   PubMed Web of Science ®Google Scholar
• Soufflet N, Boschetti G, Roblin X, et al. Concentrations of ustekinumab during induction therapy associate with remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2019 Mar 6. pii: S1542-3565(19)30248-4. doi: 10.1016/j.cgh.2019.02.042 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Van Den Bemt BJ, Den Broeder AA, Wolbink GJ, et al. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol. 2013;76(6):939–945.
   PubMed Web of Science ®Google Scholar
• Teresa J, Chamaida PR, Ana MF, et al. Predictive value of serum infliximab levels at induction phase in rheumatoid arthritis patients. Open Rheumatol J. 2017;11:75–87.
   PubMedGoogle Scholar
• Mulleman D, Chu Miow Lin D, Ducourau E, et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit. 2010;32(2):232–236.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tsuji H, Ishida-Yamamoto A, et al. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40(1):39–42.
   PubMed Web of Science ®Google Scholar
• Wilkinson N, Tsakok T, Dand N, et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Invest Dermatol. 2019;139(1):115–123.
   PubMed Web of Science ®Google Scholar
• Menting SP, Coussens E, Pouw MF, et al. developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment. JAMA Dermatol. 2015;151(6):616–622.
   PubMed Web of Science ®Google Scholar
• Chen D-Y, Chen Y-M, Hsieh T-Y, et al. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology (Oxford). 2016;55(1):143–148.
   PubMed Web of Science ®Google Scholar
• Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513–518.
   PubMed Web of Science ®Google Scholar
• Senabre Gallego JM, Rosas J, Marco-Mingot M, et al. Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. Rheumatol Int. 2019 Mar 21. [ Epub ahead of print]. DOI:10.1007/s00296-019-04288-7
   PubMed Web of Science ®Google Scholar
• Van Den Berghe N, De Keyser E, Soenen R, et al. Clinical response correlates with 4-week post injection ustekinumab concentrations in moderate-to-severe psoriasis patients. Br J Dermatol. 2019 Apr 20. [ Epub ahead of print]. DOI:10.1111/bjd.18016
   PubMed Web of Science ®Google Scholar
• Soenen R, Meulewaeter E, Grine L, et al. Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step towards personalized therapy. J Invest Dermatol. 2019 May 5;S0022-202X(19)31504–0. Epub ahead of print. DOI:10.1016/j.jid.2019.04.012
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–940.
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Yarur A, Jossen J, et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J Crohns Colitis. 2019 Feb 13;jjz041. Epub ahead of print. DOI:10.1093/ecco-jcc/jjz041
   PubMedGoogle Scholar
• Yarur AJ, Bruss A, Naik S, et al. Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases. Dig Dis Sci. 2019;64(6):1651–1659.
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and α4β7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(5):697–705.e7.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12(5):621–626.
   PubMed Web of Science ®Google Scholar
• Brandse JF, van Den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–355.
   PubMed Web of Science ®Google Scholar
• Vande CN, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12(7):804–810.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Juncadella A, Wong D, et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Jan 21. [ Epub ahead of print]. DOI:10.1093/ecco-jcc/jjz018
   PubMedGoogle Scholar
• Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–1588.
   PubMed Web of Science ®Google Scholar
• Assa A, Matar M, Turner D, et al. Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial. J Crohn’s Colitis. 2019;13(Suppl_1):S012–S013.
   Google Scholar
• Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003.
   PubMed Web of Science ®Google Scholar
• Lucidarme C, Petitcollin A, Brochard C, et al. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Aliment Pharmacol Ther. 2019;49(2):147–154.
   PubMed Web of Science ®Google Scholar
• Petitcollin A, Brochard C, Siproudhis L, et al. Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases. Clin Pharmacol Ther. 2019 Mar 12. [ Epub ahead of print]. DOI:10.1002/cpt.1429
   PubMed Web of Science ®Google Scholar
• Papamichael K, Vande Casteele N, Gils A, et al. Long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015;13(6):1103–1110.
   PubMed Web of Science ®Google Scholar
• Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(3):514–521.
   PubMed Web of Science ®Google Scholar
• Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of re-initiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014;12(9):1474–1481.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Hebing RCF, Nurmohamed MT, et al. Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. PLoS One. 2018;13(10):e0205125.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018;154(5):1343–1351.
   PubMed Web of Science ®Google Scholar
• Lega S, Phan BL, Rosenthal CJ, et al. Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD. Inflamm Bowel Dis. 2019;25(1):134–141.
   PubMed Web of Science ®Google Scholar
• Drobne D, Kurent T, Golob S, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):880–889.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Adedokun OJ, Gasink C, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin Gastroenterol Hepatol. 2018 Sep 26;S1542-3565(18)31024–3. Epub ahead of print. DOI:10.1016/j.cgh.2018.09.033
   Web of Science ®Google Scholar
• St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(6):1451–1459.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704–707.
   PubMed Web of Science ®Google Scholar
• Goss SL, Klein CE, Jin Z, et al. Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the CONCERTO Trial. Clin Ther. 2018;40(2):309–319.
   PubMed Web of Science ®Google Scholar
• Sanmarti R, Inciarte-Mundo J, Estrada-Alarcon P, et al. Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. Ann Rheum Dis. 2015;74(8):e42.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015;678:2011–2019.
   Google Scholar
• l’Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018;77(4):484–487.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 2012;71(1):88–91.
   PubMed Web of Science ®Google Scholar
• Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(6):e0175207.
   PubMed Web of Science ®Google Scholar
• Balsa A, Sanmarti R, Rosas J, et al. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. Rheumatology (Oxford). 2018;57(4):688–693.
   PubMed Web of Science ®Google Scholar
• Jani M, Isaacs JD, Morgan AW, et al. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis. 2017;76(1):208–213.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Plasencia C, Krieckaert CL, et al. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. Ann Rheum Dis. 2014;73(12):2217–2219.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, van Den Oever I, Plasencia CH, et al. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scand J Rheumatol. 2017;46(2):87–94.
   PubMed Web of Science ®Google Scholar
• Krzysiek R, Breban M, Ravaud P, et al. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum. 2009;61(5):569–576.
   PubMedGoogle Scholar
• Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13(3):R105.
   PubMed Web of Science ®Google Scholar
• Rosas J, Llinares-Tello F, Senabre-Gallego JM, et al. Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2017;35(1):145–148.
   PubMed Web of Science ®Google Scholar
• Marsman AF, Kneepkens EL, Ruwaard J, et al. Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients. Scand J Rheumatol. 2016;45(4):331–334.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Krieckaert CLM, van der Kleij D, et al. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Reum Dis. 2015;74(10):1825–1829.
   PubMed Web of Science ®Google Scholar
• de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(4):531–535.
   PubMed Web of Science ®Google Scholar
• AWR VK, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69(3):624–625.
   PubMed Web of Science ®Google Scholar
• Paramarta JE, Baeten DL. Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther. 2014;16(4):R160.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé RB, Mease PJ, et al. Brief report: secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol. 2016;68(8):1914–1921.
   PubMed Web of Science ®Google Scholar
• van Bezooijen JS, van Doorn MBA, Schreurs MWJ, et al. prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study. Ther Drug Monit. 2017;39(4):379–386.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Toro Montecinos M, Ballescá F, et al. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. J Dermatolog Treat. 2018;29(2):140–144.
   PubMed Web of Science ®Google Scholar
• Elberdín L, Outeda M, Salvador P, et al. Positive correlation between etanercept concentration and the decrease in psoriasis area and severity index scale value. Int J Clin Pharm. 2016;38(5):1142–1148.
   PubMed Web of Science ®Google Scholar
• Detrez I, Van Steen K, Segaert S, et al. The association between etanercept serum concentration and psoriasis severity is highly age-dependent. Clin Sci (Lond). 2017;131(11):1179–1189.
   PubMed Web of Science ®Google Scholar
• Toro-Montecinos M, Ballescá F, Ferrandiz C, et al. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks. J Dermatolog Treat. 2019;30(1):35–39.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834.
   PubMed Web of Science ®Google Scholar
• Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11–12):1037–1053.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF Therapy. Am J Gastroenterol. 2017;112(5):673–676.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Osterman MT, Siegel CA, et al. Using proactive therapeutic drug monitoring of anti-tumor necrosis factor therapy in inflammatory bowel disease: from an old concept to a future standard of care? Gastroenterology. 2018;154(4):1201–1202.
   PubMed Web of Science ®Google Scholar
• Grossberg LB, Papamichael K, Feuerstein JD, et al. A survey study of gastroenterologists’ attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2017;24(1):191–197.
   PubMed Web of Science ®Google Scholar
• Samaan MA, Arkir Z, Ahmad T, et al. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Dig Liver Dis. 2018;50(5):452–456.
   PubMedGoogle Scholar
• Verdon C, Vande Casteele N, Heron V, et al. Comparison of serum concentrations of ustekinumab obtained by three commercial assays in patients with Crohn’s disease. Gastroenterology. 2019;156:S–1141.
   Web of Science ®Google Scholar
• Clarke WT, Papamichail K, Niels Vande Casteele N, et al. Infliximab and adalimumab concentrations may vary between the enzyme-linked immunosorbent assay and the homogeneous mobility shift assay in patients with inflammatory bowel disease. Gastroenterology. 2019;156:S–1141.
   Web of Science ®Google Scholar
• Vande Casteele N. Assays for measurement of TNF antagonists in practice. Frontline Gastroenterol. 2017;8:236–242.
   PubMed Web of Science ®Google Scholar
• Strik A, Berends S, Mould D, et al. Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial. J Crohn’s Colitis. 2019;13(Supplement_1):S063.
   Google Scholar
• Van Stappen T, Bollen L, Vande Casteele N, et al. Rapid test for infliximab drug concentration allows immediate dose adaptation. Clin Transl Gastroenterol. 2016;7(12):e206.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019 Mar 27;S1542-3565(19)30301–5. Epub ahead of print. DOI:10.1016/j.cgh.2019.03.037
   PubMed Web of Science ®Google Scholar